94 related articles for article (PubMed ID: 18243501)
21. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].
Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B
Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987
[TBL] [Abstract][Full Text] [Related]
22. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
[TBL] [Abstract][Full Text] [Related]
23. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
24. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
[TBL] [Abstract][Full Text] [Related]
25. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer.
Linehan WM; Lerman MI; Zbar B
JAMA; 1995 Feb; 273(7):564-70. PubMed ID: 7837390
[No Abstract] [Full Text] [Related]
26. Von Hippel-Lindau disease with multiple malignant renal tumors: the importance of genetic testing.
Shah DR; Hoeksema J; Korbet SM
Clin Nephrol; 2000 Mar; 53(3):216-21. PubMed ID: 10749302
[TBL] [Abstract][Full Text] [Related]
27. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
29. [Molecular genetic mechanism of the kidney cancer].
Nakaigawa N; Yao M; Kishida T; Kubota Y
Nihon Rinsho; 2001 Jan; 59(1):104-9. PubMed ID: 11197838
[TBL] [Abstract][Full Text] [Related]
30. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.
Karashima T; Inoue K; Fukata S; Iiyama T; Kurabayashi A; Kawada C; Shuin T
Int J Oncol; 2007 Apr; 30(4):937-45. PubMed ID: 17332933
[TBL] [Abstract][Full Text] [Related]
31. Lord of the rings: a promising novel treatment for renal cell carcinoma?
Johansson M
Eur Urol; 2011 May; 59(5):745-6. PubMed ID: 21276657
[No Abstract] [Full Text] [Related]
32. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
33. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Knauth K; Bex C; Jemth P; Buchberger A
Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
[TBL] [Abstract][Full Text] [Related]
34. Genetic basis of renal cell cancer.
Linehan WM; Gnarra JR; Lerman MI; Latif F; Zbar B
Important Adv Oncol; 1993; ():47-70. PubMed ID: 8505056
[No Abstract] [Full Text] [Related]
35. von Hippel-Lindau syndrome: a rare syndrome as the clue for the molecular basis of common renal disorders.
Neumann HP
Nephrol Dial Transplant; 1995; 10(9):1498-9. PubMed ID: 8559448
[No Abstract] [Full Text] [Related]
36. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
37. Molecularly targeted therapy in renal cell carcinoma.
Rathmell WK; Wright TM; Rini BI
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1031-40. PubMed ID: 16336094
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities.
Hansel DE; Rini BI
Expert Rev Anticancer Ther; 2008 Jun; 8(6):895-905. PubMed ID: 18533799
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation.
Schmidt L; Li F; Brown RS; Berg S; Chen F; Wei MH; Tory K; Lerman I; Zbar B
Cancer J Sci Am; 1995; 1(3):191-5. PubMed ID: 9166475
[TBL] [Abstract][Full Text] [Related]
40. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.
Gallou C; Chauveau D; Richard S; Joly D; Giraud S; Olschwang S; Martin N; Saquet C; Chrétien Y; Méjean A; Correas JM; Benoît G; Colombeau P; Grünfeld JP; Junien C; Béroud C
Hum Mutat; 2004 Sep; 24(3):215-24. PubMed ID: 15300849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]